First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer
News
A Phase 3 clinical trial evaluating the immune checkpoint inhibitor Tyvyt (sintilimab injection), in combination with the chemotherapies Taxol (paclitaxel) and Platinol (cisplatin), as a first-line treatment for esophageal squamous cell carcinoma has started ... Read more